Aquestive Therapeutics (AQST) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Aquestive Therapeutics (AQST) over the past year, gaining 57.5% versus a loss of 28.6%. Over five years, AQST leads with a +23.5% price change compared with -31.7% for PCRX. Pacira BioSciences is the larger company by market cap ($1.45 billion vs $599.9 million), about 2.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AQST | PCRX |
|---|---|---|
| Share price | $4.78 | $36.31 |
| Market cap | $599.95M | $1.45B |
| 1-day change | +0.42% | -0.22% |
| YTD return | -26.01% | +40.30% |
| 1-year return | -28.55% | +57.46% |
| 5-year return | +23.51% | -31.75% |
| P/E ratio (TTM) | — | 103.74 |
| Forward P/E | — | 10.50 |
| EPS (TTM) | $-0.66 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $726.41M |
| Revenue growth (YoY) | — | +3.63% |
| Net income (latest FY) | — | $7.03M |
| Gross margin | — | 79.39% |
| Operating margin | — | 2.64% |
| Net margin | — | 0.97% |
| 52-week high | $7.55 | $36.46 |
| 52-week low | $2.93 | $18.80 |
| Distance from 52-week high | -36.69% | -0.41% |
| Analyst consensus | none | buy |
| Avg. price target upside | +95.19% | -17.08% |
| Average volume | 2.67M | 1.03M |
| Shares outstanding | 125.51M | 39.91M |
| Employees | 147 | 825 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pacira BioSciences is about 2.4 times larger than Aquestive Therapeutics by market value ($1.45B vs $599.95M).
- PCRX has outperformed AQST by 86.0 percentage points over the past year.
About Aquestive Therapeutics
AQST stock →Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
AQST vs PCRX FAQ
Which is bigger, Aquestive Therapeutics or Pacira BioSciences?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $599.95M for Aquestive Therapeutics (AQST).
Which stock has performed better over the past year, AQST or PCRX?
PCRX returned +57.46% over the past 12 months, compared with -28.55% for AQST (price return, excluding dividends). Past performance does not predict future results.
Are Aquestive Therapeutics and Pacira BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.